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Malignant pleural effusionAbstract Background: Pleurodesis is an, if not the most, important palliative option for manage-
ment of symptomatic malignant pleural effusion (MPE). Asbestos-free calibrated talc is the most
effective agent known for pleurodesis. Unfortunately, this agent is not available in many countries
including Egypt. Doxycycline is an old agent used for pleurodesis. No data exists about doxycycline
poudrage via thoracoscopy for pleurodesis in malignant pleural effusion.
Objective: To assess the efficacy, safety and outcome of medical thoracoscopic doxycycline
poudrage in symptomatic MPE.
Methods: This is a prospective cohort clinical study. Thirty patients with symptomatic MPE
were enrolled in March 2013 through March 2014. Medical thoracoscopic pleurodesis was done
using oral forms of doxycycline. Patients were followed up for 90 days after the procedure. Efficacy
was judged both clinically and radiologically. Procedure-related complications were recorded.
Results: Patients were 20 males and 10 females. Mean age ± SD was 57.67 ± 13.29 years. The
most common primary neoplasms were lung cancer and breast cancer (both, n= 11). After 90 days,
19 out of 22 surviving patients (86.4%, 95%CI = 59.8–94.8%) had successful pleurodesis. No
procedure-related major complications were recorded. Minor adverse effects included pain
(28.6%), fever (25%) and wound infection (10.7%). Survival rate at 90 days was 78.6%. Mean
duration of hospitalization was 1.93 ± 0.92 days.
Conclusion: Doxycycline, as an old agent, when poudraged during medical thoracoscopy proved
to be safe and effective agent for pleurodesis in symptomatic malignant pleural effusion.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Sabaa),
.doi.org/
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Malignant pleural effusion (MPE) causes disabling patient
morbidity and significant health care burden. The annual inci-
dence of malignant pleural effusion in developed countries has
been predicted to be more than 500,000 new cases [1]. Malig-
nancy accounts for 44–77% of all exudative pleural effusions.
It develops in nearly half of patients with disseminated malig-
nancy [2]. The presence of a MPE signifies median overall sur-
vival of 4–6 months [3]. MPE is not curable and therefore all
treatment options are palliative [4]. Pleurodesis and indwelling
pleural catheters remain the mainstay treatment options for
MPE and recently it has been shown to be equally effective [5].
Pleurodesis through thoracoscopy could be done if the
pleura appears abnormal on direct inspection thus offers diag-
nostic and therapeutic procedures in a single sitting [6]. Talc is
considered the best known sclerosing agent especially when
used by medical thoracoscopy/pleuroscopy (MT/P). Unfortu-
nately, a serious complication can occur with its use which is
acute pneumonitis leading to acute respiratory failure [7].
Graded talc, which is the safest form [8], is not available in
many developing countries, including Egypt [9]. Also, inject-
able tetracyclines’ synthesis has been ceased worldwide [10].
Meanwhile, the oral forms of doxycycline are readily available,
inexpensive and as effective as its parenteral forms in inducing
pleurodesis [11]. Therefore, the aim of this work was to assess
the efficacy, safety and outcome of thoracoscopic pleurodesis
using doxycycline poudrage in malignant pleural effusion.Patients and methods
The study was approved by the institutional ethics committee
and an informed consent was taken from all patients before
participation in the study. The present study prospectively
enrolled 30 patients with suspected or established malignant
pleural effusion who were admitted to Alexandria Main
University Hospital (AMUH) starting on March 2014 through
March 2015.
The exclusion criteria in this study were general contraindi-
cations to thoracoscopy [12] or local contraindications includ-
ing trapped lung and previously documented hypersensitivityFigure 1 The electron microscopy pho
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on performance status or medical condition, but patients had
to be judged as capable of undergoing medical thoracoscopy.
All included patients were subjected to the followings:
Detailed history taking, full clinical examination, and routine
laboratory investigations including: coagulation profile and
radiological investigations in the form of chest X-ray and CT
chest (ultrasonography of the chest were done when needed).
Bronchoscopy was performed only if endobronchial obstruc-
tion was suspected. Thoracentesis was performed in all
patients and the pleural fluid was sent for biochemical (protein,
lactate dehydrogenase (LDH) and glucose), bacteriological
and cytological evaluation.
All patients underwent medical thoracoscopy for taking
pleural biopsies that were sent for histopathological evaluation
in order to confirm malignancy. Pleurodesis was performed via
doxycycline poudrage in the pleural space.
The oral doxycycline used was (Vibramycin, 100 mg cap-
sules, Pfizer Egypt, S.A.E Cairo.) and the dose used was
10 mg/kg body weight. The diameter of the particles of vibra-
mycin capsules was measured by electron microscopy (EM)
and particle size analyzer (Cilas 1064, Orleans, France) before
the beginning of the study to exclude the possibility of systemic
side effects (if the mean particle size was <5 lm). As demon-
strated in Figs. 1 and 2, the diameter of vibramycin’s particles
was 20.04 lm at 90% concentration with the mean particle
diameter of 12.20 lm.
Thoracoscopic doxycycline poudrage technique
All patients underwent ultrasound-guided medical thora-
coscopy with a single port. Rigid thoracoscope (Karl Storz,
GmbH &. Co., Tuttlingen, Germany) was the scope used in
the current study using an angled eye-piece, 10 mm in diame-
ter, working length at 27 cm with 6 mm working channel and
a metallic trocar with multifunctional valve with insufflation
stopcock, 11 mm in diameter and autoclavable. The procedure
was performed under moderate sedation and local anesthesia.
After systematic exploration of the chest cavity, the pleural
fluid was completely removed, mechanical adhesolysis was
done (if adhesions were present) and pleural biopsies were
taken from the suspected parietal pleural lesions.tos of vibramycin capsules’ particles.
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Figure 2 Particle size distribution curve of vibramycin capsules’ particles by CILAS particle size analyzer.
Doxycycline poudrage: An old agent for a new technique 3The particles of vibramycin capsules were evacuated under
complete aseptic technique in the container of the pneumatic
atomizer (Powder Blower with Bulb) (Karl Storz, GmbH &.
Co., Tuttlingen, Germany). The pneumatic atomizer was
introduced into the pleural space through the working channel
of rigid thoracoscope and then the powder was insufflated on
all pleural surfaces under direct observation to confirm wide
distribution of doxycycline.
To evaluate the burden of the lesions inside the pleural cav-
ity, a scoring system was adopted ranging from l to 9 [13].
Each parietal pleural surface took a score of (1, 2 or 3) accord-
ing to their involvement (discrete, diffuse or massive involve-
ment, respectively). The summation of the score for each
pleural division constitutes the total thoracoscopy scoring.
To quantify the severity of adhesions inside the pleural space,
another scoring system was followed [14]. Scoring for adhe-
sions took a score from 0 to 4.
At the end of the procedure, a chest tube was inserted in
most cases through the cannula of the trocar [15]. Drains were
removed if the chest radiograph confirmed satisfactory lung
expansion, and the 24-h drainage was less than 150 ml, withPlease cite this article in press as: E.A. Hatata et al., Doxycycline poudrage: An old ag
10.1016/j.ejcdt.2016.08.012no air leak. All patients were discharged on the same day their
chest tube was removed.
Follow up
All patients were monitored for procedure-related adverse
events. All patients were followed up for three months with
focus on re-accumulation of the MPE or the need for further
pleural interventions. Follow up was done clinically and radi-
ologically on day 7, 30 and 90 following the procedure. The
efficacy of pleurodesis was defined in three levels of response:
complete (absence of pleural fluid reaccumulation), partial
(residual pleural fluid or reaccumulation, which did not require
further intervention or remained asymptomatic), and failed
(additional pleural procedures were necessary).
Statistical analysis
Raw data were transformed into coding sheets using Micro-
soft Excel 2010 then analyzed using IBM SPSS softwareent for a new technique, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/
All eligible 
paents = 30
Completed the 
study = 28
Alive at 90 days 
= 22
Successful 
pleurodesis = 19
Failed 
pleurodesis = 3
Paents died 
before 90 days
Excluded from 
the study = 2
Figure 3 Flow chart demonstrating the distribution of the
studied patients along the follow up period (90 days).
4 E.A. Hatata et al.package (IBM SPSS Statistics for Windows, Version 20.0.,
IBM Corp., Armonk, NY). Qualitative data were described
using number and percent. Quantitative data were described
using range (minimum and maximum), mean and standard
deviation, median and inter quartile range (IQR). The signifi-
cance of the obtained results was judged at the 5% level of
significance.
Results
The characteristics of the study population and their primary
malignancies as diagnosed by the histopathological examina-
tion of their thoracoscopic pleural biopsies are noted in
Table 1. The commonest presenting symptom in all studied
patients (100%) was dyspnea. Also common was chest pain
(73.3%), cough (73.3%) and weight loss (50%) as secondary
symptoms. The commonest radiological CT chest findings
were pleural nodules and pleural thickening presenting in
63.3% and 60% of our studied patients, respectively. Malig-
nant cells were detected in the pleural fluid of 26.7% of the
studied patients.
Intra-thoracoscopic examination of the studied patients
revealed that most of the detected pleural lesions were located
on the costo-parietal pleura as it was involved in 29 (96.7%)
patients followed by the visceral pleura (93.3%) then the
diaphragmatic pleura (80%). Pericardial lesions were detected
in one patient. Pleural nodules were the commonest lesions
detected during the procedure (in 27 (90%) patients). The med-
ian thoracoscopic scoring value was 7. Regarding the detected
grades of adhesions, grade 1 was detected in 6 (20%) patients,
grade 2 in 2 (6.7%) patients and grade 3 in 3 (10%) patients.
As demonstrated in the flow chart in Fig. 3, all eligible
patients in the current study were 30 patients, 2 patients were
excluded from further analysis either due to the detection of
extensive adhesions during thoracoscopy in one patient or
trapped lung in follow up chest X-ray in another patient hin-
dering full lung expansion and success of pleurodesis. Further-
more, the 90-day mortality-rate after the procedure was
21.4%. Death of these 6 patients was related to the progression
of their malignancy rather than the procedure.
The outcome of thoracoscopic doxycycline poudrage
among the studied patients along the follow up period ofTable 1 Patients’ characteristics.
Number of patients 30
Sex M: 10; F: 20
Age in years Mean (range) 57.67 (37–80)
History of previous malignancy n (%)
Negative 16 (53.3%)
Positive 14 (46.7%)
Primary tumor n (%)
Lung 11 (36.7%)
Breast 11 (36.7%)
Gastric cancer 2 (6.7%)
Malignant lymphoma 2 (6.7%)
Ovarian cancer 1 (3.3%)
Pancreatic cancer 1 (3.3%)
Uterine cancer 1 (3.3%)
Unknown primary 1 (3.3%)
M=male, F = female, n = number.
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chest tube removal after successful pleurodesis which was the
same duration of post-procedural hospitalization was 1.93
± 0.92 days. After exclusion of the 6 patients who died before
the completion of their follow up period, the rate of successful
pleurodesis was 86.4% with 13.6% of patients having recur-
rences. The successful pleurodesis rates among all eligible/
treated/ full lung expansion/alive patients after 90 days of fol-
low up are summarized in Table 3.
The Kaplan-meier curve in Fig. 4 demonstrates the overall
survival of the studied patients till 90 days after the procedure.
The percentage of overall survival at 90 days after the proce-
dure was 78.6%. The survival of the studied patients was
strongly linked to primary tumor type of MPE (p= 0.006)
rather than the pleural tumor burden as represented by thora-
coscopic scoring (p= 0.1).
No post-procedural major complications were encountered
in the current study. There were minor post-procedural com-
plications showed in Table 4. Complications were resolved
by follow up only or by other therapeutic measures like
non-steroidal anti-inflammatory drugs (NSAIDs), local and
systemic antibiotics, higher level chest tube insertion for
pneumothorax and modified tunneled pleural catheters TPCs
insertion for failed patients.Table 2 The outcome of thoracoscopic doxycycline poudrage
among the studied patients (number of patients = 28).
Outcome No. %
Success 25 89.3
Complete response 5 17.9
Partial response 20 71.4
Failure 3 10.7
Initial failure 2 7.1
Recurrence 1 3.6
gent for a new technique, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/
Table 3 Successful pleurodesis rates among all eligible/treated/full lung expansion/alive patients after 90 days of follow up.
No. Alive after 90 days
without recurrence, No.
% 95% CI
All eligible patients 30 19 63.3 46.1–80.6
Eligible, treated 29 19 65.5 48.2–82.8
Full lung expansion, treated 28 19 67.9 50.6–85.2
Full lung expansion, treated, alive 22 19 86.4 59.8–94.8
CI = confidence interval.
78.6%
Figure 4 Kaplan-Meier survival curve for overall survival
among the studied patients.
Table 4 The percentage of occurrence of major and minor
complications among the studied patients (n= 28).
No. %
Major complications:
Death related to the procedure, ARDS, Acute
respiratory failure
0 0.0
Minor complications
Surgical emphysema 14 50.0
Fever >38 C 7 25.0
Wound infection 3 10.7
Pneumothorax 1 3.6
Empyema 0 0.0
Pain VAS
Mild 1 3.6
Moderate 4 14.3
High 15 53.6
Very high 8 28.6
ARDS: Acute respiratory distress syndrome, VAS: visual analogue
score.
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shown to affect outcome of thoracoscopic doxycycline poud-
rage; primary tumor type, pleural tumor burden, grades of
adhesions, CT chest findings, protein and glucose content of
pleural fluid, age and sex of the studied population.
Discussion
Malignant pleural effusion causes significant reduction in the
quality of life of patients with advanced malignancy. The med-
ian overall survival after its diagnosis is estimated to be around
4–6 months. The management of malignant pleural effusion is
usually palliative. Pleurodesis is the most widely acceptable
method. A variety of agents could be used to induce pleurode-
sis. Thoracoscopic talc poudrage is considered the best method
of pleurodesis. Graded talc is not available in many developing
countries including Egypt. However, oral forms of doxycy-
cline, tetracycline derivative, are available, effective and cheap
and could be a good alternative in inducing pleurodesis.
Doxycycline has been used in several studies to induce pleu-
rodesis for palliative management of malignant pleural effu-
sions and for recurrent pneumothoraces [16–18]. This was
owed to its similar clinical success rates to tetracycline,
although there were no direct studies comparing success rates
of both agents, together [19].
According to Teixeira et al. [20], tetracycline derivatives
induce pleurodesis by creating an acute pleural injury with
subsequent inflammation and fibrosis. Furthermore, the
deposition of collagen after instillation of doxycycline or tetra-
cycline might be enhanced by their inhibitory effect on matrix
metalloproteinases in the human pleural fluid after instillation
of these drugs in vitro and in vivo [21].Please cite this article in press as: E.A. Hatata et al., Doxycycline poudrage: An old ag
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cess rates ranging from 80 to 92% [22,23]. Unfortunately, the
definition of success of pleurodesis as well as the length of
follow-up period show notable variation in the literature. This
leads to complicated comparative assessment of the different
agents used for pleurodesis within studies [24].
The ATS/ERS consensus [2] stated that data from compar-
ative studies of different pleurodesis techniques should be
reported with and without inclusion of patients who died
within 1 month of pleurodesis. Therefore, the percent of global
response (the sum of the complete and partial responses) to
thoracoscopic doxycycline poudrage in the present study was
89.3% and at 90 days of follow up it became 86.4% due to
exclusion of six patients who died because of the progression
of their malignancy.
The observed pleurodesis success rate of thoracoscopic
doxycycline poudrage (TDP) in the present study falls within
the reported success rates for thoracoscopic talc poudrage,
the best sclerosing agent to date, varying between 75% and
95% [25,26] and higher than that reported from the traditional
method of doxycycline instillation pleurodesis ranging between
67% and 86% [22,23,27].
The traditional method of doxycycline instillation among
studies is tube thoracostomy with tube connected to continu-
ous wall suction [22]. This method was less comfortable requir-
ing patient rotation to disperse the sclerosing agent and limited
patient mobility along the whole period of tube drainage [28].
Also, it was time consuming requiring longer hospital stay
when compared to the more recent techniques includingent for a new technique, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/
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duration of tube drainage after tube thoracostomy and doxy-
cycline instillation as demonstrated by Mohamed and Hassan
[29]. and Putnam et al. [30], was 4.2 ± 2.6 days and 6.5 days,
respectively.
It is greatly interesting to note that pleurodesis has been
accomplished within 2 days of (TDP) in most of the studied
patients (88%) in the current study. This means that the previ-
ously discussed problems [27,31] when using doxycycline as a
sclerosing agent have been bypassed by this new method. As
it showed less recurrence rate, less need for repeated dosing
and shorter duration of chest tube retain in place. These disad-
vantages were greatly increasing the cost of the traditional
method of doxycycline pleurodesis [32].
In comparison with the relatively more recent method of
doxycycline instillation, the study of Seaton et al. [33] has
reported the highest 30-days success-rate of small bore catheter
pleurodesis which was 95%. This was very close to our success
rate after the same period (92.5%). However, the diagnosis of
malignant pleural effusion (which determines operability in
lung cancer patients) [34] was confirmed only in 71.4% of
the studied patients in the latter study due to the previously
mentioned limited diagnostic yield of cytological examination
of pleural fluid [35]. Also, it is worth noting that the mean
duration of tube drainage after sclerotherapy in that study
was 5 days ranging from 2 days to 10 days while in ours the
mean duration was 2 days ranging from 1 day to 5 days as a
maximum.
On the other hand, it is widely known that the dilemma of
undiagnosed exudative effusions with negative pleural fluid
cytology and suspected malignancy could not be actually
worked out without the help of medical thoracoscopy [12].
This was one of the great advantages of this method of pleu-
rodesis. Near half (46.6%) of our studied patients had undiag-
nosed recurrent exudative pleural effusion. They had no
history of previous malignancy and negative cytological exam-
ination for malignant cells after thoracentesis.
Those patients have been enrolled in our study due to their
highly suspicious clinical and radiological history [36] to get
benefit from the high diagnostic and therapeutic efficacy of
medical thoracoscopy (achieving diagnosis and management
of pleural effusion in the same session) [37,38]. Afterwards,
the malignant etiology of their effusion has been confirmed
by histo-pathological examination of their thoracoscopic biop-
sies. And those who had negative pleural biopsy for malig-
nancy were excluded from the study.
It is also worth noting that despite the presence of malig-
nant cells in the pleural fluid samples, medical thoracoscopy
is still indicated for determination of the extent and stage
(operability) of primary tumor [39,40] and obtaining tissues
for further workup (e.g., in cases of breast cancer metastases
or lymphoma) [41,42].
Although talc is considered the best known sclerosing agent
[7,8], there were serious concerns about the safety of talc with
reports of acute respiratory distress syndrome ARDS follow-
ing its administration. De Campos et al. [7] in the review for
their 15 years of experience with thoracoscopic talc poudrage
showed major morbidity in the form of empyema in 4%, re-
expansion pulmonary edema in 2.2%, and respiratory failure
1.3% of their patients. Nevertheless, in the systematic review
by Tan et al. [25] for the evidence on the effectiveness of man-
agement of MPE, 36 cases of pneumonitis have been reportedPlease cite this article in press as: E.A. Hatata et al., Doxycycline poudrage: An old a
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tality occurred in 3.7% of patients receiving talc insufflation
and 2.9% of patients receiving talc slurry in the study of Dres-
ler et al. [43].
However, when graded talc was used and small particles
were avoided, this complication has been omitted [25]. In con-
sistent with this, Maskell et al. [44] and Rossi et al. [45] have
suggested that ARDS after talc pleurodesis is mainly related
to the particle size of the talc used. Unfortunately, graded talc
is not available in many developing countries, including Egypt
due to the stringent requirements needed for its manufacture
[10].
Therefore, the size of the particles of doxycycline capsules
(vibramycin, 100 mg capsule, Pfizer) has been measured at
the beginning of the study to assess the probability of systemic
inflammation after its insufflation. The mean particle diameter
was 12.20 lm. This means it is larger than the injurious size (5–
10 lm) [46] that would cause systemic inflammation. Thus,
according to doxycycline particles’ size, it is safe to be insuf-
flated into the pleural space. So, the availability, accessibility
and feasibility of thoracoscopic doxycycline poudrage made
the procedure a good and effective alternative for pleurodesis
in malignant pleural effusion.
Comparing our results with that of iodo-povidone, another
available and inexpensive sclerosing agent, Banawan et al. [47]
have demonstrated success rates of 73.3% and 86.7% follow-
ing wide bore and thoracoscopic instillation of iodopovidone.
In agreement with this, Agarwal et al. [48] in the systematic
review for assessment of efficacy and safety of iodopovidone
showed pooled success rate of 88.7%. However, they also
reported that iodine can cause severe allergic reactions, espe-
cially in patients with allergic diathesis and also may precipi-
tate thyrotoxicosis in subclinical hyperthyroidism cases as it
has been shown in the same study [48].
To date and to our knowledge, the study of Elnady and
Sakr [49] is the first and the only study evaluating the efficacy
of thoracoscopic doxycycline poudrage in inducing pleurodesis
in MPE. In consistency with our study, success was achieved in
25 patients of 27 studied patients (92.6%) after 30 days of fol-
low up and the mean duration of tube drainage was 1.52 days,
versus 89.3% success rate and 1.93 ± 0.92 days for duration of
tube drainage in our study. Differences between Elnady study
and our study are in the study design being (retrospective vs.
prospective) and the total follow up period after the procedure
(30 days only vs. 30 & 90 days).
Many studies reported serious respiratory complications
after talc pleurodesis even with low dose of 2 g and with differ-
ent techniques of application [19]. None of these major compli-
cations has occurred after thoracoscopic doxycycline poudrage
as it has been demonstrated by Elnady and Sakr [49] and also
in our series.
Notably, minor complications have been encountered in the
current study. The most frequent ones were post-procedural
pain and fever. Pain and fever were the most reported compli-
cations following the use of different sclerosing agents as well
as with variable methods of administration as demonstrated in
the five English speaking countries’ survey done by Lee et al.
[19] In agreement with this, Shouman et al. [11] and Bakr
et al. [50] showed that post-pleurodesis chest pain and fever
were the commonest problems encountered in their studies
occurring in all of their studied groups following the use of dif-
ferent sclerosing agents but with variable percent of incidence.gent for a new technique, Egypt. J. Chest Dis. Tuberc. (2016), http://dx.doi.org/
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patients and in agreement with Kolschmann et al. [51], survival
outcome in the present study was strongly linked to the pri-
mary tumor type. This was demonstrated by the higher 90-
day survival rate among patients with breast cancer than in
those with lung cancer and any other type of primary cancer
(p= 0.006). Meanwhile, the pleural tumor burden (thoraco-
scopic scoring) did not predict survival outcome in the current
study. This was explained in the literature [20] by the differ-
ences in tumor aggression among different types of metastases
and the different degrees of response to chemotherapy. This
was obviously demonstrated in breast cancer patients in whom
pleural tumor burden was larger but their response to
chemotherapy is greater than any other tumor type [13,52].
The current study provides a circumstantial evidence for
that medical thoracoscopy can be valuable in magnification
of panoramic view of the pleura as well as allows adequate
biopsy specimens access for histologic examination and also
gives the option for therapeutic procedures to be performed
like pleurodesis. Thoracoscopic doxycycline pleurodesis is
highly effective and safe in the longer term management of
patients with MPE.
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